291 related articles for article (PubMed ID: 30091061)
1. Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.
Hari P; Khandelwal P; Satpathy A; Hari S; Thergaonkar R; Lakshmy R; Sinha A; Bagga A
Pediatr Nephrol; 2018 Dec; 33(12):2299-2309. PubMed ID: 30091061
[TBL] [Abstract][Full Text] [Related]
2. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
[TBL] [Abstract][Full Text] [Related]
3. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Long-Term Atorvastatin Therapy on Carotid Intima-Media Thickness of Children With Dyslipidemia.
Karapostolakis G; Vakaki M; Attilakos A; Marmarinos A; Papadaki M; Koumanidou C; Alexopoulou E; Gourgiotis D; Garoufi A
Angiology; 2021 Apr; 72(4):322-331. PubMed ID: 33242982
[TBL] [Abstract][Full Text] [Related]
5. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Davidson M; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Setze C; Carlson DM; Stolzenbach J
Cardiovasc Drugs Ther; 2012 Aug; 26(4):349-58. PubMed ID: 22622962
[TBL] [Abstract][Full Text] [Related]
6. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Taylor AJ; Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Vernalis MN
Circulation; 2002 Oct; 106(16):2055-60. PubMed ID: 12379573
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
8. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
[TBL] [Abstract][Full Text] [Related]
9. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
Ikeda K; Takahashi T; Yamada H; Matsui K; Sawada T; Nakamura T; Matsubara H;
Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia.
Pareek A; Chandurkar N; Thulaseedharan NK; Legha R; Agarwal M; Mathur SL; Salkar HR; Pednekar S; Pai V; Sriram U; Khyalappa R; Parmar M; Agrawal N; Dhruv U; Saxena S
Curr Med Res Opin; 2015 Nov; 31(11):2105-17. PubMed ID: 26371518
[TBL] [Abstract][Full Text] [Related]
11. Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
Nakagomi A; Shibui T; Kohashi K; Kosugi M; Kusama Y; Atarashi H; Shimizu W
J Atheroscler Thromb; 2015; 22(11):1158-71. PubMed ID: 26084792
[TBL] [Abstract][Full Text] [Related]
12. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
[TBL] [Abstract][Full Text] [Related]
13. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial.
Spring S; Simon R; van der Loo B; Kovacevic T; Brockes C; Rousson V; Amann-Vesti B; Koppensteiner R
Thromb Haemost; 2008 Jan; 99(1):182-9. PubMed ID: 18217152
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naïve dyslipidemic patients.
Kumar M; Rehan HS; Puri R; Yadav M; Gupta LK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S64-S67. PubMed ID: 30595323
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
17. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.
Hari P; Khandelwal P; Smoyer WE
Pediatr Nephrol; 2020 Sep; 35(9):1601-1619. PubMed ID: 31302760
[TBL] [Abstract][Full Text] [Related]
18. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
Ardoin SP; Schanberg LE; Sandborg CI; Barnhart HX; Evans GW; Yow E; Mieszkalski KL; Ilowite NT; Eberhard A; Imundo LF; Kimura Y; Levy D; von Scheven E; Silverman E; Bowyer SL; Punaro L; Singer NG; Sherry DD; McCurdy DK; Klein-Gitelman M; Wallace C; Silver RM; Wagner-Weiner L; Higgins GC; Brunner HI; Jung L; Soep JB; Reed AM; Thompson SD;
Ann Rheum Dis; 2014 Mar; 73(3):557-66. PubMed ID: 23436914
[TBL] [Abstract][Full Text] [Related]
19. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
20. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
Shioji K; Izuhara M; Mitsuoka H; Uegaito T; Matsuda M;
Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
